Alto Neuroscience, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | $45.6M | $47.0M | $30.3M | — |
| Operating expenses | $66.4M | $68.6M | $37.8M | — |
| Operating income | -$66.4M | -$68.6M | -$37.8M | — |
| Interest expense | $2.5M | $1.4M | $1.4M | — |
| Income tax expense | $0 | $0 | $0 | — |
| Net income | -$63.2M | -$61.4M | -$36.3M | — |
| Balance Sheet | ||||
| Cash and equivalents | $176.5M | $168.2M | $82.5M | — |
| Current assets | $177.7M | $169.3M | $85.4M | — |
| Total assets | $184.7M | $177.5M | $86.6M | — |
| Current liabilities | $11.3M | $10.0M | $5.6M | — |
| Total liabilities | $33.5M | $26.1M | $16.8M | — |
| Total debt | — | $10.0M | — | — |
| Stockholders' equity | $151.1M | $151.5M | -$71.7M | -$38.4M |
| Cash Flow Statement | ||||
| Cash from operations | -$51.8M | -$47.4M | -$33.4M | — |
| Depreciation and amortization | $661,000 | $502,000 | $373,000 | — |
| Stock-based compensation | $8.1M | $7.6M | $2.9M | — |
| Capital expenditure | $24,000 | $2.1M | $470,000 | — |
| Free cash flow | -$51.8M | -$49.5M | -$33.9M | — |
Shares outstanding 35.1M · Free float 84.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.